A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 7, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions
Fabry Disease
Interventions
OTHER

No intervention

This is a non-interventional study

Trial Locations (18)

100034

Peking University First Hospital, Beijing

100191

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

150086

The Second Affiliated Hospital of Harbin Medical University, Harbin

210008

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing

210029

The First Affiliated Hospital With NanJing Medical University(JiangSu Province Hospital), Nanjing

215006

The First Affiliated Hospital Of Soochow University, Suzhou

230001

The First Affiliated Hospital Of USTC (AnHui Provincial Hospital), Hefei

300222

TianJin Chest Hospital, Tianjin

310009

The Second Affiliated Hospital ZheJiang University School Of Medicine, Hangzhou

350001

Fuzhou University Provincial Affiliated Hospital, Fuzhou

515031

ShanTou Central Hospital, Shantou

518053

The University Of Hong Kong-ShenZhen Hospital, Shenzhen

610041

West China Hospital of Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Xi 'an Jiaotong University, Xi'an

710061

The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an

050000

The Second Hospital of Hebei Medical University, Shijiazhuang

030001

Second Hospital Of ShanXi Medical University, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT07187440 - A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease | Biotech Hunter | Biotech Hunter